EU Specialty Pharma to See Product Launches But Limited Clinical Data Next Year -- Market Talk

Dow Jones12-10

0705 GMT - Several new product launches are expected for the EU specialty pharma sector next year but limited clinical trial data, RBC Capital Markets analysts say in a note. Galderma should launch its skin drug Nemluvio, to treat prurigo nodularis in the U.S. and Europe; Ipsen will bring its rare liver disease drug Iqirvo to market; and Sandoz is set to introduce a biosimilar version of chronic autoimmune disease treatment, Stelara, the analysts say. Genmab's multiple myeloma drug Phase 2 result will be the key trial, determining whether Johnson & Johnson will in-license the drug, they say. (helena.smolak@wsj.com)

(END) Dow Jones Newswires

December 10, 2024 02:05 ET (07:05 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490050075?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-10 15:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490050075","market":"us","top_or_hot":-1,"title":"EU Specialty Pharma to See Product Launches But Limited Clinical Data Next Year -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0705 GMT - Several new product launches are expected for the EU specialty pharma sector next year but limited clinical trial data, RBC Capital Markets analysts say in a note. Galderma should launch its skin drug Nemluvio, to treat prurigo nodularis in the U.S. and Europe; Ipsen will bring its rare liver disease drug Iqirvo to market; and Sandoz is set to introduce a biosimilar version of chronic autoimmune disease treatment, Stelara, the analysts say. Genmab's multiple myeloma drug Phase 2 result will be the key trial, determining whether Johnson &amp; Johnson will in-license the drug, they say. (helena.smolak@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 10, 2024 02:05 ET (07:05 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EU Specialty Pharma to See Product Launches But Limited Clinical Data Next Year -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEU Specialty Pharma to See Product Launches But Limited Clinical Data Next Year -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-10 15:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>0705 GMT - Several new product launches are expected for the EU specialty pharma sector next year but limited clinical trial data, RBC Capital Markets analysts say in a note. Galderma should launch ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4156","symbol_name":"煤与消费用燃料","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2490050075","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490050075","pubTimestamp":1733814300,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0705 GMT - Several new product launches are expected for the EU specialty pharma sector next year but limited clinical trial data, RBC Capital Markets analysts say in a note. Galderma should launch its skin drug Nemluvio, to treat prurigo nodularis in the U.S. and Europe; Ipsen will bring its rare liver disease drug Iqirvo to market; and Sandoz is set to introduce a biosimilar version of chronic autoimmune disease treatment, Stelara, the analysts say. Genmab's multiple myeloma drug Phase 2 result will be the key trial, determining whether Johnson & Johnson will in-license the drug, they say. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4156":"煤与消费用燃料","GMAB":"Genmab A/S","BK4139":"生物科技","JNJ":"强生"},"translate_title":"欧盟专业制药公司明年将推出产品，但临床数据有限——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GMAB":0.9,"JNJ":0.9},"content_text":"0705 GMT - Several new product launches are expected for the EU specialty pharma sector next year but limited clinical trial data, RBC Capital Markets analysts say in a note. Galderma should launch its skin drug Nemluvio, to treat prurigo nodularis in the U.S. and Europe; Ipsen will bring its rare liver disease drug Iqirvo to market; and Sandoz is set to introduce a biosimilar version of chronic autoimmune disease treatment, Stelara, the analysts say. Genmab's multiple myeloma drug Phase 2 result will be the key trial, determining whether Johnson & Johnson will in-license the drug, they say. (helena.smolak@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 10, 2024 02:05 ET (07:05 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490050075"}